-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evexomostat in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Evexomostat in Solid Tumor Drug Details:Evexomostat (SDX-7320) is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Genistein in Pulmonary Radiation Toxicity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Genistein in Pulmonary Radiation Toxicity Drug Details: Genistein (BIO-300) is under development as a medical...
-
Thematic Analysis
New![]()
Synthetic Biology – Thematic Intelligence
Synthetic Biology Thematic Report Overview Synthetic biology is commonly abbreviated to synbio. It involves the manipulation of genetic material to enhance specific characteristics or, conversely, stifle them. The ability to perform this manipulation quickly, precisely, and at a low cost has the potential to impact numerous sectors. From developing environmentally friendly luxury materials to novel cancer therapeutics and even the use of DNA as a new form of data storage, the forthcoming field of synbio unlocks several new realms of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NG-641 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NG-641 in Pancreatic Cancer Drug Details: NG-641 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Lung Cancer Drug Details: QBS-10072S is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIO-11006 in Chronic Obstructive Pulmonary Disease (COPD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIO-11006 in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: BIO-11006 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alisertib in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Small-Cell Lung Cancer Drug Details: Alisertib (MLN-8237) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alisertib in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: Alisertib (MLN-8237) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIO-106 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIO-106 in Solid Tumor Drug Details: BIO-106 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alisertib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.